Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®.
Panminerva Med. 2021 Mar ;63(1):46-50. PMID: 33541059
BACKGROUND: The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenolin idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM).
METHODS: A SM and a Pycnogenol+SM group were formed. Pycnogenolsupplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM.
RESULTS: Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenolgroup and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI<26), not using any drug. All subjects had an elevated level of oxidative stress (OS) at inclusion. All routine blood tests - and all inflammatory and rheumatic tests - were within the normal range at inclusion and at the end of the study. No safety or tolerability problems were observed. The percentage of patients using NSAIDs (non-steroidal anti-inflammatory drugs) as rescue medications in the observation period was significantly higher in the SM management group (P<0.05) in comparison with the supplement group. The percentage of patients using corticosteroids as rescue medication was significantly higher in the SM group (P<0.05). The percentage of subjects with the symptoms/complaints decreased significantly, considering each symptom, with Pycnogenolafter 4 weeks in comparison with the SM (P<0.05).
CONCLUSIONS: Pycnogenolsupplementation appears to control and reduce the intensity of common symptoms and complaints - especially pain-related - associated with FM. Pycnogenolcould be a 'soft', safe supplementation and prevention method to manage the symptoms of most of these patients, even for longer periods, reducing the need for drugs.